Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats

Journal of Psychopharmacology
S SnigdhaJ C Neill

Abstract

Weight gain induced by some second-generation anti-psychotics such as olanzapine has emerged as a most debilitating side-effect. This study investigates whether co-administration with either ziprasidone or aripiprazole, which have little propensity to induce weight gain, can attenuate the hyperphagic effect of olanzapine. Female hooded-Lister rats (n=8 per group) were treated acutely with either vehicle, olanzapine (1 mg/kg), ziprasidone (1 mg/kg), aripiprazole (2 mg/kg) or olanzapine in combination with ziprasidone or aripiprazole and placed in automated locomotor activity (LMA) boxes with preweighed palatable mash. Food intake and LMA were measured for 60 min postdrug treatment. All olanzapine-treated groups demonstrated significant increases in food intake (P<0.001). This effect was attenuated following co-administration of olanzapine with either ziprasidone or aripiprazole (P<0.001), neither of which affected food intake alone. The lack of hyperphagia induced by aripiprazole and ziprasidone may reflect an inherent pharmacological mechanism preventing weight gain.

References

Jan 1, 1989·Psychopharmacology·J C Neill, S J Cooper
Jul 7, 1988·European Journal of Pharmacology·J C Neill, S J Cooper
Apr 13, 2002·Journal of Psychopharmacology·Zoe Thornton-JonesGavin P Reynolds
Dec 31, 2002·Journal of Psychopharmacology·Andrew J GoudieJason C G Halford
Dec 31, 2002·Psychoneuroendocrinology·H Nasrallah
Jan 14, 2003·The Journal of Clinical Psychiatry·Diana O Perkins
Jan 24, 2003·Journal of Neural Transmission·F M TheisenJ Hebebrand
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wesley K KroezeBryan L Roth
May 22, 2003·Pharmacology, Biochemistry, and Behavior·B PouzetS Velschow
Aug 27, 2004·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·Jambur AnanthSarath Gunatilake
Sep 1, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M J FellK M Marshall
Sep 11, 2004·Journal of Psychopharmacology·Gavin P Reynolds
Nov 24, 2004·European Journal of Pharmacology·Shona L KirkGavin P Reynolds
Jan 25, 2005·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Vicki L EllingrodDel Miller
Nov 11, 2005·Journal of Psychopharmacology·Peter Haddad
Jun 20, 2006·Psychopharmacology·Julie Minet-RinguetRenaud de Beaurepaire
Aug 5, 2006·Schizophrenia Research·A I GreenUNKNOWN HGDH Study Group
Sep 13, 2006·The Journal of Clinical Psychiatry·Shih-Ku Lin, Chih-Ken Chen

❮ Previous
Next ❯

Citations

Aug 19, 2009·Psychopharmacology·Shona L KirkGavin P Reynolds
Jan 3, 2012·Metabolism: Clinical and Experimental·Subin ParkJin Pyo Hong
Jan 3, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·David J G WatsonKevin C F Fone
Nov 26, 2009·Pharmacology & Therapeutics·Gavin P Reynolds, Shona L Kirk
Oct 10, 2013·The International Journal of Neuropsychopharmacology·E M van der ZwaalR A H Adan
Jun 3, 2016·Psychopharmacology·Louise BenarrochMargaret K Hahn
Dec 1, 2011·Therapeutic Advances in Psychopharmacology·Gavin P Reynolds
Sep 12, 2017·Journal of Psychopharmacology·Gavin P Reynolds, Olga O McGowan
Mar 25, 2019·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Gavin P ReynoldsMichael K Harte
Dec 3, 2011·CNS Drugs·James L RoerigJames E Mitchell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here